JP2020526591A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526591A5
JP2020526591A5 JP2020523041A JP2020523041A JP2020526591A5 JP 2020526591 A5 JP2020526591 A5 JP 2020526591A5 JP 2020523041 A JP2020523041 A JP 2020523041A JP 2020523041 A JP2020523041 A JP 2020523041A JP 2020526591 A5 JP2020526591 A5 JP 2020526591A5
Authority
JP
Japan
Prior art keywords
disorders
compound
disease
compound according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523041A
Other languages
English (en)
Japanese (ja)
Other versions
JP7114702B2 (ja
JP2020526591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/068366 external-priority patent/WO2019011802A1/en
Publication of JP2020526591A publication Critical patent/JP2020526591A/ja
Publication of JP2020526591A5 publication Critical patent/JP2020526591A5/ja
Application granted granted Critical
Publication of JP7114702B2 publication Critical patent/JP7114702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523041A 2017-07-11 2018-07-06 新規置換キサンチン誘導体 Active JP7114702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180721.7 2017-07-11
EP17180721 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2020526591A JP2020526591A (ja) 2020-08-31
JP2020526591A5 true JP2020526591A5 (cg-RX-API-DMAC7.html) 2021-08-12
JP7114702B2 JP7114702B2 (ja) 2022-08-08

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523041A Active JP7114702B2 (ja) 2017-07-11 2018-07-06 新規置換キサンチン誘導体

Country Status (32)

Country Link
US (1) US10329292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3652176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7114702B2 (cg-RX-API-DMAC7.html)
KR (1) KR102714554B1 (cg-RX-API-DMAC7.html)
CN (1) CN110997675B (cg-RX-API-DMAC7.html)
AR (1) AR112448A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018299824B2 (cg-RX-API-DMAC7.html)
CA (1) CA3066922A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019015102A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125014T1 (cg-RX-API-DMAC7.html)
DK (1) DK3652176T3 (cg-RX-API-DMAC7.html)
EA (1) EA039526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2903268T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220029T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057600T2 (cg-RX-API-DMAC7.html)
IL (1) IL271799B (cg-RX-API-DMAC7.html)
LT (1) LT3652176T (cg-RX-API-DMAC7.html)
MX (1) MX394089B (cg-RX-API-DMAC7.html)
MY (1) MY200797A (cg-RX-API-DMAC7.html)
PE (1) PE20200861A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020500079A1 (cg-RX-API-DMAC7.html)
PL (1) PL3652176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3652176T (cg-RX-API-DMAC7.html)
RS (1) RS62826B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410851B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201912168TA (cg-RX-API-DMAC7.html)
SI (1) SI3652176T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI801398B (cg-RX-API-DMAC7.html)
UA (1) UA124793C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019011802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231208B2 (en) * 2018-03-05 2025-01-23 Gfb (Abc), Llc Imidazodiazepinediones and methods of use thereof
US12291532B2 (en) 2018-12-12 2025-05-06 Boehringer Ingelheim International Gmbh Substituted xanthines as modulators of TRPC5 activity
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
KR20250141831A (ko) 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
MX370372B (es) * 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Similar Documents

Publication Publication Date Title
Hays Enhancing rehabilitative therapies with vagus nerve stimulation
RU2015143466A (ru) Нейроактивные стероиды и способы их применения
JP2007500757A5 (cg-RX-API-DMAC7.html)
HRP20220029T1 (hr) Supstituirani derivati ksantina
JP2019524822A5 (cg-RX-API-DMAC7.html)
SG10201903474PA (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
JP2019512528A5 (cg-RX-API-DMAC7.html)
JP2016535786A5 (cg-RX-API-DMAC7.html)
JP2012521994A5 (cg-RX-API-DMAC7.html)
HRP20221240T1 (hr) Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe
JP2020520911A5 (cg-RX-API-DMAC7.html)
EP3483283C0 (en) METHOD FOR SCREENING AGENTS FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY INTERLEUKIN 6, INTERLEUKIN 13, TNF, G-CSF, CXCL1, CXCL2 OR CXCL5 AND AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY INTERLEUKIN 6, INTERLEUKIN 13, TNF, G-CSF, CXCL1, CXCL2 OR CXCL5
Hassanzadeh et al. Effectuality of cognitive-behavioral therapy on the life expectancy of patients with multiple sclerosis
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
Kentner Neuroprotection and recovery from early-life adversity: considerations for environmental enrichment
JP2022512374A5 (cg-RX-API-DMAC7.html)
WO2020123977A3 (en) Glial fibrillary acidic protein targeting immuno-and aptamer-based-therapy for neuroinjury, neurodegeneration, neuro-disease, and neuro-repair
Yang et al. Effect of Chaihu-Shugan-San on the mRNA expression of the 5-HT1A receptor and cellular proliferation in the hippocampus of epileptic rats with depression
JP2022512373A5 (cg-RX-API-DMAC7.html)
Turner et al. Superficial siderosis associated with anterior horn cell dysfunction
Firouzian et al. Is ketamine–propofol mixture (ketofol) an appropriate alternative induction agent for electroconvulsive therapy?
WO2024196772A3 (en) Mdma enantiomers
MX2023003273A (es) Ligandos de nlrx1.
Rahmatinejad et al. Efficacy of Transcranial Direct Current Stimulation in Reducing Symptoms in Patients with Major Depressive Disorder: A Randomized Controlled Trial
RU2016152150A (ru) Ботулинический токсин для применения в лечении паратонии